PB103
/ Chongqing Precision Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
February 16, 2025
Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients
(clinicaltrials.gov)
- P1/2 | N=24 | Recruiting | Sponsor: Precision Biotech Taiwan Corp. | Trial completion date: Dec 2024 ➔ Dec 2027 | Trial primary completion date: Dec 2024 ➔ Dec 2027
Trial completion date • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • HLA-B • HLA-C • HLA-DRB1
November 18, 2023
Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients
(clinicaltrials.gov)
- P1/2 | N=24 | Recruiting | Sponsor: Precision Biotech Taiwan Corp. | Trial primary completion date: Jun 2022 ➔ Dec 2024
Combination therapy • Trial primary completion date • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • HLA-B • HLA-C • HLA-DRB1
1 to 2
Of
2
Go to page
1